First Ever FDA Authorized Over-the-Counter At-Home Rapid Test Kit For Coronavirus Backed by Biden Administration, as Global WholeHealth Partners Corp. Pioneers The Only Biodegradable Plant Based Plastic for Medical Devices

San Clemente, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp, (OTC:GWHP) a multinational medical diagnostics supplier of over 70+ products with 56 already FDA approved and several approved for export only including Dengue, Ebola, Zika, Malaria and also offering one of the largest lines of tests for CoViD19 SARS2, announces that they are pioneers of the only biodegradable plant based plastic for medical devices after receiving provisional patent.

As the Biden administration announced on Monday a big push to make rapid COVID-19 home tests available with a $230 million federal contract through the Department of Defense, Global WholeHealth Partners Corp. (OTC:GWHP) CEO, Charles Strongo, said, “We understand the growth needed in the in-vitro diagnostic segment and the need for more rapid tests, and at the same time we understand that there is also a need to GO GREEN.”

“We took that challenge and created a proper mix of plant based material which is 100% biodegradable, to make a plastic that is biodegradable to help the medical industry,” said Mr. Strongo.

Global WholeHealth Partners acknowledges the fact that tens of millions of plastic medical devices are used every month in the US alone and hundreds of millions throughout the world. Just in the US alone, Healthcare facilities across America generate around 14,000 tons (28,000,000 lbs.) of waste per day. Up to 25% of this is made up of plastic products.

“We know firsthand how busy the Healthcare Industry is as it’s fighting off diseases, especially during this global pandemic; we felt compelled to do more to combat the Medical Waste problem by lending our biodegradable technology,” Strongo commented.

Global WholeHealth Partners Corp recently entered into a License Agreement with Charles Strong in which under the terms of the Agreement, the Company has the exclusive license to manufacture, sell and license to be manufactured the only Biodegradable plastic for medical devices.

President Biden’s Executive Order on Establishing the COVID-19 Pandemic Testing Board was recently applauded by Charles Strongo, CEO of Global WholeHealth Partners Corp (OTC:GWHP), as a step in the right direction.

The Biden administration on Monday announced a big push to make rapid COVID-19 home tests available with a $230 million federal contract to an Australian company.

The Department of Defense’s deal will allow Ellume to open a U.S. factory and make 19 million rapid tests each month, 8.5 million of which will be provided to the federal government, officials said.

Ellume is the only company to get U.S. Food and Drug Administration authorization to make a home COVID-19 test that doesn’t need a lab or a medical provider’s prescription. The 15-minute test includes a nasal swab for users to collect a sample and place into a cartridge and is used with a smartphone app that displays results.

When Ellume gained FDA authorization in December, the company said it would sell the rapid tests for $30. But the company did not have manufacturing capability to make the tests widely available to consumers.

On this announcement, Charles Strongo, CEO of Global WholeHealth Partners Corp., said, “They should come talk to us; we have been doing this for years.”

About Global:

Global WholeHealth Partners Corp., a multinational supplier of over 70+ with 56 products FDA approved and several approved for export only including Dengue, Ebola, Zika, and Malaria and also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the pandemic out of control in the United States, the nation’s coronavirus testing system is starting to strain again.

About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more—193 million a month, according to one report—to be effective.

The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test.

Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: investors@gwhpcorp.com

www.gwhpcorp.com

Forward-Looking Statements

This press release contains “forward-looking statements.”  Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.